title: Interaction of fibrin with VE-cadherin and anti-inflammatory effect of fibrin-derived fragments.
abstract: BACKGROUND
  The interaction of the fibrin βN-domain with VE-cadherin on endothelial cells is implicated in transendothelial migration of leukocytes, and the β15-42 fragment representing part of this domain has been shown to inhibit this process. However, our previous study revealed that only a dimeric (β15-66)(2) fragment, corresponding to the full-length βN-domain and mimicking its dimeric arrangement in fibrin, bound to VE-cadherin.
  
  
  OBJECTIVE
  To test our hypothesis that dimerization of β15-42-containing fragments increases their affinity for VE-cadherin and ability to inhibit transendothelial migration of leukocytes.
  
  
  METHODS
  Interaction of β15-42-containing fragments with VE-cadherin was characterized by ELISA and surface plasmon resonance. The inhibitory effect of such fragments was tested in vitro with a leukocyte transendothelial migration assay and in vivo with mouse models of peritonitis and myocardial ischemia-reperfusion injury.
  
  
  RESULTS
  First, we prepared the monomeric β15-42 and β15-64 fragments and their dimeric forms, (β15-44)(2) and (β15-66)(2) , and studied their interaction with the fibrin-binding domain of VE-cadherin, VE-cad(3). The experiments revealed that both dimeric fragments bound to VE-cad(3) with high affinity, whereas the affinities of β15-42 and β15-64 were significantly lower. Next, we tested the ability of these fragments to inhibit leukocyte transmigration in vitro and infiltration into the inflamed peritoneum in vivo, and found that the inhibitory effects of the dimers on these processes were also superior. Furthermore, (β15-44)(2) significantly reduced myocardial injury induced by ischemia-reperfusion.
  
  
  CONCLUSIONS
  The results confirm our hypotheses and indicate that (β15-66)(2) and (β15-44)(2) , which exhibited much higher affinity for VE-cadherin, are highly effective in suppressing inflammation by inhibiting leukocyte transmigration.
authors.affiliation: Center for Vascular and Inflammatory Diseases and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Yakovlev
authors.forename: Y
authors.initials: Y
authors.lastname: Gao
authors.forename: C
authors.initials: C
authors.lastname: Cao
authors.forename: L
authors.initials: L
authors.lastname: Chen
authors.forename: D K
authors.initials: DK
authors.lastname: Strickland
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: L
authors.initials: L
authors.lastname: Medved
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D015820:Cadherins / Q000378:metabolism*; D002316:Cardiotonic Agents / Q000494:pharmacology; D002465:Cell Movement; D019281:Dimerization; D042783:Endothelial Cells / Q000378:metabolism; D005337:Fibrin / Q000378:metabolism*; D005338:Fibrin Fibrinogen Degradation Products / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D066298:In Vitro Techniques; D007249:Inflammation / Q000378:metabolism* / Q000517:prevention & control*; D007962:Leukocytes / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D010538:Peritonitis / Q000517:prevention & control; D054730:Protein Interaction Domains and Motifs; D000099152:Cadherin 5
chemical_list: D015703:Antigens, CD; D015820:Cadherins; D002316:Cardiotonic Agents; D005337:Fibrin; D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; D000099152:Cadherin 5; C033786:fibrinogen Bbeta (15-42)